Evidence map›Paper›PMID 37064335›Full record

ArticleMolecular syndromology2023

Two Patients Diagnosed as Succinate Dehydrogenase Deficiency: Case Report.

Burcu Civelek Ürey, Ahmet Cevdet Ceylan, Büşranur Çavdarlı, Ayşegül Neşe Çıtak Kurt, Oya Kıreker Köylü, Burak Yürek, Çiğdem Seher Kasapkara

Open access · greenAbstract readCase Reports
In one paragraph

Article in Molecular syndromology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Molecular syndromology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Burcu Civelek ÜreyPediatric Metabolism, Ankara City Hospital, Ankara, Turkey.
Ahmet Cevdet CeylanMedical Genetic, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Büşranur ÇavdarlıMedical Genetic, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Ayşegül Neşe Çıtak KurtPediatric Neurology, Ankara City Hospital, Ankara, Turkey.
Oya Kıreker KöylüPediatric Metabolism, Ankara City Hospital, Ankara, Turkey.
Burak YürekPediatric Metabolism, Ankara City Hospital, Ankara, Turkey.
Çiğdem Seher KasapkaraPediatric Metabolism, Ankara City Hospital, Ankara, Turkey.
Memorial Ankara Hospital · TRAnkara Yıldırım Beyazıt University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introductıon: Succinate dehydrogenase deficiency, also known as mitochondrial complex II deficiency, is a rare inborn error of metabolism, accounting for approximately 2% of mitochondrial disease. Mutations in the four genes Case Report: Herein, we report the first case of a 7-year-old child who was diagnosed as having succinate dehydrogenase deficiency. The affected child presented at 1 year of age with encephalopathy and developmental regression following viral illnesses. MRI changes supported a clinical diagnosis of Leigh syndrome and c.1328C>Q and c.872A>C Discussion and Conclusion: There are several very different presentations including Leigh syndrome, epileptic encephalopathy, and cardiomyopathy. Some cases present following viral illness; this feature is not specific to mitochondrial complex II deficiency and occurs in many other mitochondrial disease presentations. There is no cure for complex II deficiency, though some reported patients showed clinical improvement following riboflavin therapy. Riboflavin is not the only therapeutic intervention that is available to patients with an isolated complex II deficiency and various other compounds have shown promise in the treatment of symptoms, including L-carnitine and ubiquinone. Treatment alternatives such as parabenzoquinone EPI-743 and rapamycin are under study in the treatment of the disease.

Indexed as

Leigh syndrome phenotypeMetabolic diseasesMitochondrial diseaseSuccinate dehydrogenase deficiencyWhole-exome sequencing

Identifiers

PMID37064335
PMCPMC10090973
OpenAlexW4315926768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.